{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.65","upperLimit":"3.44","value":"2.39"},{"groupId":"OG001","lowerLimit":"1.97","upperLimit":"2.62","value":"2.08"},{"groupId":"OG002","lowerLimit":"1.29","upperLimit":"3.21","value":"2.43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"28"}],"units":"Participants"}],"description":"Cyclophosphamide plasma concentration-time data are collected in consolidation cycle 1. Individual estimates of cyclophosphamide clearance are obtained using post hoc analysis.","dispersionType":"Full Range","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG002","title":"High-Risk Group"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who received cyclophosphamide during consolidation cycle 1 and had samples collected for PK analysis.","reportingStatus":"POSTED","timeFrame":"Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion","title":"Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 1","type":"SECONDARY","unitOfMeasure":"L/h/m^2"}